Well, all the GLP-1 meds work on the same GLP-1 receptor. Tirzepatide *might* activate it more strongly, and Reta possibly has less nausea because of the GIP action, but they all hit the same receptor. So, logically, they're all risky for NAION, even if it hasn't been observed yet. Semaglutide's...